Frederick Faßlrinner

Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial

Frederick Faßlrinner, Johannes Schetelig, Andreas Burchert et al. · The Lancet Haematology · 2018 · 91 citations

Medicine, Hematology, Immunology +16

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells

Claudia Arndt, Liliana R. Loureiro, Anja Feldmann et al. · OncoImmunology · 2020 · 40 citations · Full text

Medicine, Immunology, Oncology +17

Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells

Frederick Faßlrinner, Manja Wobus, Regina Duryagina et al. · Experimental Hematology · 2012 · 34 citations · Full text

Life Sciences, Cell Biology, Immunology +14

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy

Enrico Kittel-Boselli, Karla Elizabeth González Soto, Liliana R. Loureiro et al. · Cancers · 2021 · 34 citations · Full text

Life Sciences, Immunology, Oncology +17

Midostaurin abrogates <scp>CD</scp>33‐directed Uni<scp>CAR</scp> and <scp>CD</scp>33‐<scp>CD</scp>3 bispecific antibody therapy in acute myeloid leukaemia

Frederick Faßlrinner, Claudia Arndt, Stefanie Koristka et al. · British Journal of Haematology · 2019 · 17 citations · Full text

Life Sciences, Immunology, Oncology +17